Misra Paraish, Lang Eddy, Clement Catherine M, Brison Robert J, Rowe Brian H, Borgundvaag Bjug, Langhan Trevor, Magee Kirk, Stenstrom Rob, Perry Jeffrey J, Birnie David, Wells George A, Xue X, Innes G, Stiell Ian G
Division of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute.
J Atr Fibrillation. 2013 Apr 6;5(6):645. doi: 10.4022/jafib.645. eCollection 2013 Apr-May.
Guidelines strongly recommend long-term anticoagulation with warfarin for patients with newly recognized AF who have high embolic risk by virtue of a CHADS (Congestive Heart Failure, Hypertension, Age >65, Diabetes, History of Stroke) score ≥ 2. The goal of this study was to determine patterns of emergency department-initiated anticoagulation among eligible patients discharged from Canadian centers with an episode of recent-onset atrial fibrillation and flutter (RAFF) and determine if decision-making is driven by the CHADS score or other factors. This was accomplished by examining health records using uniform case identification and data abstraction as well as centralized quality control; it was conducted in 8 Canadian university emergency departments over a 12-month period. Eligible patients for this analysis demonstrated RAFF requiring emergency management, were not already taking warfarin and were not admitted to hospital. Univariate analyses were conducted using T-test or Chi-square to select factors associated with anticoagulation initiation at a significance level of p < 0.15 and multiple logistic regression was employed to evaluate independent predictors after adjustment for confounders. Among 633 eligible patients, only 21 out of 120 patients (18%) with a CHADS score ≥ 2 received anticoagulation and among 70 patients who were given anticoagulation only 21 (30%) had a CHADS score ≥ 2. Independent predictors of anticoagulation included age by 10-year strata: (OR = 1.7; 95% CI 1.3 - 2.1), heparin use in the anticoagulation (OR = 9.6; 95% CI 4.9 - 18.9), a new prescription for metoprolol (OR = 9.6; 95% CI 4.9 - 18.9) and being referred to cardiology for follow-up (OR = 5.6; 95% CI 2.6 - 12.0). CHADS ≥ 2 doubled the likelihood of being prescribed anticoagulation (OR= 2.0; 95% CI 1.5 - 3.5) but was not an independent predictor. It was thus determined that patients discharged from the emergency department in this study were not prescribed anticoagulation in keeping with current recommendations. This practice gap merits further investigation and may benefit from educational efforts or enhanced support for anticoagulation use from the emergency department.
指南强烈推荐,对于新确诊的房颤患者,若其CHADS(充血性心力衰竭、高血压、年龄>65岁、糖尿病、卒中史)评分≥2,具有高栓塞风险,则应长期使用华法林进行抗凝治疗。本研究的目的是确定加拿大各中心因近期发作的房颤和心房扑动(RAFF)发作而出院的符合条件患者中,急诊科启动抗凝治疗的模式,并确定决策是否由CHADS评分或其他因素驱动。这是通过使用统一的病例识别和数据提取以及集中质量控制来检查健康记录来完成的;该研究在8个加拿大大学急诊科进行,为期12个月。本分析的符合条件患者表现为需要紧急处理的RAFF,尚未服用华法林,且未住院。使用T检验或卡方检验进行单变量分析,以选择与抗凝治疗启动相关的因素,显著性水平为p<0.15,并采用多元逻辑回归来评估在调整混杂因素后的独立预测因素。在633名符合条件的患者中,CHADS评分≥2的120名患者中只有21名(18%)接受了抗凝治疗,在接受抗凝治疗的70名患者中,只有21名(30%)的CHADS评分≥2。抗凝治疗的独立预测因素包括按10年分层的年龄:(比值比=1.7;95%置信区间1.3 - 2.1)、抗凝治疗中使用肝素(比值比=9.6;95%置信区间4.9 - 18.9)、美托洛尔的新处方(比值比=9.6;95%置信区间4.9 - 18.9)以及被转诊至心脏病科进行随访(比值比=5.6;95%置信区间2.6 - 12.0)。CHADS≥2使开具抗凝治疗处方的可能性增加一倍(比值比=2.0;95%置信区间1.5 - 3.5),但不是独立预测因素。因此确定,本研究中从急诊科出院的患者未按照当前建议开具抗凝治疗处方。这种实践差距值得进一步调查,可能受益于教育努力或急诊科对抗凝治疗使用的更多支持。